DTH Response to Reduce Herpes Simplex Virus Outbreaks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for herpes simplex virus (HSV) infections, such as antiviral therapy, do not provide a cure and often require lifelong prophylactic use, with frequent and severe outbreaks remaining a significant issue for many patients.
Innovation Solution
Administering a substance that induces a delayed-type hypersensitivity (DTH) reaction locally at an HSV lesion site during an outbreak to train the immune system, using substances like squaric acid dibutyl ester (SADBE) or recall antigens to enhance immune response and reduce future outbreak frequency and severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral therapy is used to treat HSV infection, then symptoms and viral shedding are reduced, but the infection cannot be cured and lifelong prophylactic therapy is required
Solution Approach 1:
The patent applies preliminary action by inducing a DTH response before the virus can establish permanent latency. The method involves administering a substance that triggers a delayed-type hypersensitivity reaction at the site of HSV lesions during active outbreaks, thereby training the immune system to recognize and attack herpes-infected cells before they can hide in nerve ganglia. This preemptive immune activation is the key differentiator from conventional antivirals that only suppress symptoms.
Solution Approach 2:
The patent uses an intermediary substance to bridge the gap between the immune system and HSV-infected cells. The DTH-inducing substance acts as a mediator that recruits and activates T cells, which then directly target and destroy herpes-infected cells. This intermediary approach allows the immune system to naturally eliminate the virus without requiring continuous antiviral medication.
2Productivity
If prophylactic antiviral therapy is administered continuously, then outbreak frequency is reduced, but the treatment must be maintained for the patient's entire life
Solution Approach 1:
The patent employs preliminary action by inducing immune memory during active outbreaks. The DTH response training occurs when the virus is most accessible and visible to the immune system, creating long-lasting immunological memory that provides ongoing protection without requiring continuous medication. This preliminary immune education replaces the need for lifelong prophylaxis.
Solution Approach 2:
The patent enables the immune system to serve itself by creating self-sustaining immunological memory. Once the DTH response is induced and T cells are trained to recognize HSV antigens, the immune system autonomously maintains surveillance and responds to future outbreaks without external intervention. This self-service mechanism eliminates the need for continuous antiviral therapy.
3Reliability
If DTH response is induced at the lesion site during outbreak, then immune system is trained to recognize HSV, but the substance must be applied repeatedly at the site
Solution Approach 1:
The patent uses a distant site intermediary approach where the DTH-inducing substance is applied at a location remote from the HSV lesions (such as the forearm or thigh). This distant application site serves as an intermediary location that still triggers systemic immune responses and T cell activation against HSV, eliminating the need to apply substances directly to sensitive or inconvenient lesion sites while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly reduces the frequency and severity of subsequent HSV outbreaks, as demonstrated in clinical trials, with a single application of SADBE on the upper arm preventing future outbreaks in a statistically significant manner without further application at the lesion site.
Implementation Method 1
administering a substance that induces a delayed-type hypersensitivity (DTH) reaction locally at a site of an HSV lesion during an outbreak. This causes T cells to swarm the area of the lesion, which has a high concentration of virus.
Data Source
AI summary
A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site other than at the site of an HSV lesion to induce a DTH response during one or more outbreaks of the HSV infection. The method reduces the number of HSV outbreaks in persons experiencing outbreaks.